Boardroom Alpha
Start trial
10-Q primary document
SRZN · Quarterly Report (Form 10-Q) · Filed November 7, 2025

Surrozen Inc — 10-Q exhibit

srzn-ex10_2.htm
Surrozen Inc on Boardroom Alpha
EX-10.2

Exhibit 10.2

SUBLEASE EXTENSION AGREEMENT

This SUBLEASE EXTENSION AGREEMENT (this “Extension Agreement”) is made as of May 15, 2025, by and between Surrozen Operating, Inc., a Delaware corporation (“Sublessor”), and Nura Bio, Inc., a Delaware corporation (“Sublessee”).

RECITALS

WHEREAS, Sublessor and Sublessee are parties to that certain Sublease dated as of April 16, 2024 (the “Sublease”), for approximately 6,102 rentable square feet located on the fourth floor of the building located at 171 Oyster Point Boulevard, South San Francisco, California (the

“Subleased Premises”); and

WHEREAS, the current term of the Sublease commenced on May 15, 2024 and, unless earlier terminated, is set to continue on a month-to-month basis beginning on the 12-month anniversary of the Commencement Date; and

WHEREAS, Sublessor and Sublessee desire to extend the Term of the Sublease on the terms and conditions set forth below.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants and conditions herein contained, the parties agree as follows:

1.
Extension of Term. The Term of the Sublease is hereby extended for an additional twelve (12) months, commencing on the 12-month anniversary of the Commencement Date and continuing through the day immediately preceding the 24-month anniversary of the Commencement Date (the “Extended Term”), unless earlier terminated pursuant to the Sublease.
2.
Base Rent. During the Extended Term, Sublessee shall pay Base Rent in accordance with Section 4.A. of the Sublease as follows:

 

Beginning Day / Month

Base Rent

May 15, 2025 (1st Day/Month of Extended Term)

$36,139.09 per month

 

3.
Effect of Extension. Except as expressly amended by this Extension Agreement, all of the terms and conditions of the Sublease shall remain unmodified and in full force and effect,

including Sublessee’s obligation to pay Additional Rent and perform all obligations in accordance with the Sublease.

4.
No Waiver. Nothing in this Extension Agreement shall be construed as a waiver by either party of any rights or remedies under the Sublease or applicable law.
5.
Counterparts. This Extension Agreement may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. Electronic signatures shall be deemed valid and enforceable.

 

IN WITNESS WHEREOF, the parties have executed this Extension Agreement as of the date first written above.

 

SUBLESSOR:

Surrozen Operating, Inc.

 

 

By:

 /s/ Charles Williams

Name:

 Charles Williams

Title:

 CFO/COO

 

 

SUBLESSEE:

Nura Bio, Inc.

 

 

By:

 /s/ Shilpa Sambashivan

Name:

 Shilpa Sambashivan

Title:

 Chief Executive Officer

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer